sotrovimab or xevudy market, sotrovimab or xevudy market share, sotrovimab or xevudy market growth, sotrovimab or xevudy market size, sotrovimab or xevudy market analysis, sotrovimab or xevudy market forecast
How much is the sotrovimab or xevudy market worth, and how is it expected to expand?
The sotrovimab or xevudy market size has XX (HCAGR) in recent years. It will grow from $XX million in 2024 to $XX million in 2025 at a compound annual growth rate (CAGR) of XX%. The growth in the historic period can be attributed to rise in prevalence of COVID-19, the increase in demand for effective monoclonal antibody treatments, growth in awareness of high-risk patient care, rise in government funding, and rise in collaborations between pharmaceutical companies.
The sotrovimab or xevudy market size is expected to see XX (FCAGR) in the next few years. It will grow to $XX million in 2029 at a compound annual growth rate (CAGR) of XX%. The growth in the forecast period can be attributed to rising emergence of new COVID-19 variants, increasing focus on monoclonal antibody therapies, expanding healthcare access in developing regions, rising government support for pandemic preparedness, and growing telehealth services for treatment delivery. Major trends in the forecast period include advancements in vaccine manufacturing technologies, innovation in formulations, integration of telehealth, advancements in antibody production technologies, and advancements in antibody engineering.
Get Your Free Sample of The Global Sotrovimab Or Xevudy Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=20383&type=smp
Which industry factors have accelerated the sotrovimab or xevudy market’s expansion?
The rise in the prevalence of COVID-19 cases is expected to drive the growth of the sotrovimab or xevudy market going forward. COVID-19 is a disease caused by the SARS-CoV-2 virus, spreading through respiratory droplets and causing symptoms from mild fever to severe respiratory issues. Vaccines and hygiene practices help prevent its spread. COVID-19 cases are increasing due to factors such as new variants, reduced immunity, eased restrictions, seasonal indoor gatherings, and uneven vaccine coverage. Sotrovimab treats high-risk COVID-19 patients by neutralizing the virus early, preventing severe outcomes such as hospitalization or death. For instance, in March 2023, according to a report published by the Office for National Statistics, a UK-based government department for official statistics, as of March 2023, an estimated 1.9 million people in the UK (2.9% of the population) reported COVID. Most (92%) had COVID-19 over 12 weeks earlier, with 69% experiencing symptoms for over a year and 41% for over two years. Therefore, the rise in the prevalence of COVID cases is going to drive the growth of the sotrovimab or xevudy market.
What are the primary segments of the sotrovimab or xevudy market?
The sotrovimab or xevudy market covered in this report is segmented –
1) By Indication: COVID-19 Early Treatment; Post-Exposure Prophylaxis
2) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
3) By End User: Pediatric; Adult; Geriatric
Order your report now for swift delivery
https://www.thebusinessresearchcompany.com/report/sotrovimab-or-xevudy-global-market-report
Which firms are leading the sotrovimab or xevudy market?
Major companies operating in the sotrovimab or xevudy market are GSK plc; Vir Biotechnology Inc.
Which market trends are set to define the future of the sotrovimab or xevudy market?
The key trend in the sotrovimab or xevudy market is the emphasis on strategic investments to boost research and development, expand production capacities, and improve access to the drug. These partnerships are crucial for accelerating distribution and ensuring broader availability, especially in high-need regions. For instance, in January 2022, GSK plc, a UK-based pharmaceutical company, partnered with Vir Biotechnology Inc., a US-based biotechnology company, and announced a significant agreement with the United States government to purchase additional supplies of sotrovimab, a monoclonal antibody authorized for the early treatment of COVID-19. This agreement highlights the ongoing need for effective treatments as the pandemic continues to evolve. Sotrovimab is specifically designed for adults and adolescents at high risk of progressing to severe COVID-19, offering a vital option for those who do not require oxygen supplementation. This recent agreement reflects GSK and Vir’s broader strategy to ensure that sotrovimab remains accessible despite the emergence of new variants of the virus.
Which geographic trends are shaping the sotrovimab or xevudy market, and which region has the highest market share?
North America was the largest region in the sotrovimab or xevudy market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the sotrovimab or xevudy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Does The Sotrovimab Or Xevudy Market Report 2025 Offer?
The sotrovimab or xevudy market research report from The Business Research Company offers global market size, growth rate, regional shares, competitor analysis, detailed segments, trends, and opportunities.
Sotrovimab (Xevudy) is a monoclonal antibody treatment developed for the management of COVID-19. It is specifically designed to target the SARS-CoV-2 spike protein, preventing the virus from entering and infecting human cells. Sotrovimab is used for treating mild-to-moderate COVID-19 in patients at high risk of progressing to severe illness, offering an effective therapeutic option in early-stage infections.
Purchase the exclusive report now to unlock valuable market insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20383
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
